Parental preferences for CDKN2A/p16 testing of minors

Jennifer M. Taber, Lisa G. Aspinwall, Wendy Kohlmann, Reed Dow, Sancy Leachman

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, there is a well-established and avoidable environmental influence and a documented benefit of early detection. Methods: We surveyed 61 CDKN2A/p16 mutation-tested adults from two kindreds about their attitudes toward genetic testing of minors immediately posttesting and 2 years later. Results: Overall, 86.9% expressed support of melanoma genetic testing of minors, with the importance of risk awareness (77.4%) and the likelihood of improved prevention and screening behaviors (69.8%) as the most frequently cited potential benefits. Among mutation carriers, 82.6% wanted genetic testing for their own children. These preferences remained stable over a 2-year period. Most respondents (62.3%) favored complete involvement of their children in genetic counseling and test reporting; 19.7% suggested that children be tested but not informed of the results. Concerns about inducing psychological distress or compromising children's decision autonomy were infrequently cited. Testing preferences did not vary by respondent age, gender, or melanoma history. Conclusion: Respondents strongly supported melanoma genetic testing of minors, with most citing improved health behavior as a likely outcome. We discuss options for melanoma genetic counseling and testing of minors.

Original languageEnglish (US)
Pages (from-to)823-838
Number of pages16
JournalGenetics in Medicine
Volume12
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Minors
Genetic Testing
Melanoma
Genetic Counseling
Mutation
Health Behavior
Psychology
Surveys and Questionnaires

Keywords

  • CDKN2A
  • children
  • familial melanoma
  • genetic counseling
  • prevention

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Parental preferences for CDKN2A/p16 testing of minors. / Taber, Jennifer M.; Aspinwall, Lisa G.; Kohlmann, Wendy; Dow, Reed; Leachman, Sancy.

In: Genetics in Medicine, Vol. 12, No. 12, 12.2010, p. 823-838.

Research output: Contribution to journalArticle

Taber, JM, Aspinwall, LG, Kohlmann, W, Dow, R & Leachman, S 2010, 'Parental preferences for CDKN2A/p16 testing of minors', Genetics in Medicine, vol. 12, no. 12, pp. 823-838. https://doi.org/10.1097/GIM.0b013e3181f87278
Taber, Jennifer M. ; Aspinwall, Lisa G. ; Kohlmann, Wendy ; Dow, Reed ; Leachman, Sancy. / Parental preferences for CDKN2A/p16 testing of minors. In: Genetics in Medicine. 2010 ; Vol. 12, No. 12. pp. 823-838.
@article{f67baad76d104d92849d6bfa95b46ce5,
title = "Parental preferences for CDKN2A/p16 testing of minors",
abstract = "Purpose: Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, there is a well-established and avoidable environmental influence and a documented benefit of early detection. Methods: We surveyed 61 CDKN2A/p16 mutation-tested adults from two kindreds about their attitudes toward genetic testing of minors immediately posttesting and 2 years later. Results: Overall, 86.9{\%} expressed support of melanoma genetic testing of minors, with the importance of risk awareness (77.4{\%}) and the likelihood of improved prevention and screening behaviors (69.8{\%}) as the most frequently cited potential benefits. Among mutation carriers, 82.6{\%} wanted genetic testing for their own children. These preferences remained stable over a 2-year period. Most respondents (62.3{\%}) favored complete involvement of their children in genetic counseling and test reporting; 19.7{\%} suggested that children be tested but not informed of the results. Concerns about inducing psychological distress or compromising children's decision autonomy were infrequently cited. Testing preferences did not vary by respondent age, gender, or melanoma history. Conclusion: Respondents strongly supported melanoma genetic testing of minors, with most citing improved health behavior as a likely outcome. We discuss options for melanoma genetic counseling and testing of minors.",
keywords = "CDKN2A, children, familial melanoma, genetic counseling, prevention",
author = "Taber, {Jennifer M.} and Aspinwall, {Lisa G.} and Wendy Kohlmann and Reed Dow and Sancy Leachman",
year = "2010",
month = "12",
doi = "10.1097/GIM.0b013e3181f87278",
language = "English (US)",
volume = "12",
pages = "823--838",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Parental preferences for CDKN2A/p16 testing of minors

AU - Taber, Jennifer M.

AU - Aspinwall, Lisa G.

AU - Kohlmann, Wendy

AU - Dow, Reed

AU - Leachman, Sancy

PY - 2010/12

Y1 - 2010/12

N2 - Purpose: Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, there is a well-established and avoidable environmental influence and a documented benefit of early detection. Methods: We surveyed 61 CDKN2A/p16 mutation-tested adults from two kindreds about their attitudes toward genetic testing of minors immediately posttesting and 2 years later. Results: Overall, 86.9% expressed support of melanoma genetic testing of minors, with the importance of risk awareness (77.4%) and the likelihood of improved prevention and screening behaviors (69.8%) as the most frequently cited potential benefits. Among mutation carriers, 82.6% wanted genetic testing for their own children. These preferences remained stable over a 2-year period. Most respondents (62.3%) favored complete involvement of their children in genetic counseling and test reporting; 19.7% suggested that children be tested but not informed of the results. Concerns about inducing psychological distress or compromising children's decision autonomy were infrequently cited. Testing preferences did not vary by respondent age, gender, or melanoma history. Conclusion: Respondents strongly supported melanoma genetic testing of minors, with most citing improved health behavior as a likely outcome. We discuss options for melanoma genetic counseling and testing of minors.

AB - Purpose: Genetic testing of minors is controversial, as ethical considerations depend on multiple aspects of the particular disease and familial context. For melanoma, there is a well-established and avoidable environmental influence and a documented benefit of early detection. Methods: We surveyed 61 CDKN2A/p16 mutation-tested adults from two kindreds about their attitudes toward genetic testing of minors immediately posttesting and 2 years later. Results: Overall, 86.9% expressed support of melanoma genetic testing of minors, with the importance of risk awareness (77.4%) and the likelihood of improved prevention and screening behaviors (69.8%) as the most frequently cited potential benefits. Among mutation carriers, 82.6% wanted genetic testing for their own children. These preferences remained stable over a 2-year period. Most respondents (62.3%) favored complete involvement of their children in genetic counseling and test reporting; 19.7% suggested that children be tested but not informed of the results. Concerns about inducing psychological distress or compromising children's decision autonomy were infrequently cited. Testing preferences did not vary by respondent age, gender, or melanoma history. Conclusion: Respondents strongly supported melanoma genetic testing of minors, with most citing improved health behavior as a likely outcome. We discuss options for melanoma genetic counseling and testing of minors.

KW - CDKN2A

KW - children

KW - familial melanoma

KW - genetic counseling

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=78650677274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650677274&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e3181f87278

DO - 10.1097/GIM.0b013e3181f87278

M3 - Article

VL - 12

SP - 823

EP - 838

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 12

ER -